Nanobac About To Start Manufacturing Nanotechnology Based Diagnostic Tests

Nanobac Pharmaceuticals Inc. announces that its proprietary CE marked Nano-Capture ELISA assay and Nano-Sero IgG ELISA assay currently manufactured by the Company’s subsidiary in Kuopio, Finland, will be made in the United States for use in clinical trials, FDA approval and expanded distribution.

The Company’s diagnostics detect Calcifying Nano Particles (CNPs) which are linked to several diseases associated with pathologic calcification. The Company believes that its diagnostics will serve as biomarkers allowing for earlier identification, diagnosis, and treatment of such diseases.

“The technology transfer of our proprietary diagnostic to a FDA approved U.S. manufacturing facility is a hallmark event for our company,” commented Dr. Benedict Maniscalco, Nanobac’s Co-Chair and Chief Medical Officer. “Bringing our manufacturing to the United States will potentially allow us to make our diagnostic a standard of care in U.S. Healthcare and represents a key step to transition from a research oriented company to one that rapidly develops products for sales and marketing worldwide.”